Malignant effusions and immunogenic tumour-derived exosomes
Background Exosomes derived from tumours are small vesicles released in vitro by tumour
cell lines in culture supematants. To assess the role of these exosomes in vivo, we examined …
cell lines in culture supematants. To assess the role of these exosomes in vivo, we examined …
[HTML][HTML] Randomized trial of cytoreductive surgery for relapsed ovarian cancer
…, BJ Mosgaard, F Selle, F Guyon, C Pomel… - … England Journal of …, 2021 - Mass Medical Soc
Background Treatment for patients with recurrent ovarian cancer has been mainly based on
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications
BACKGROUND: The purpose was to determine the factors influencing nodal involvement
and topography of pelvic and paraaortic node involvement in ovarian carcinoma. STUDY …
and topography of pelvic and paraaortic node involvement in ovarian carcinoma. STUDY …
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French …
Background Despite a high response rate to front-line therapy, prognosis of epithelial
ovarian carcinoma (EOC) remains poor. Approaches that combine Cytoreductive Surgery (CRS) …
ovarian carcinoma (EOC) remains poor. Approaches that combine Cytoreductive Surgery (CRS) …
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
…, S Greggi, PT Jensen, F Selle, F Guyon, C Pomel… - 2020 - ascopubs.org
6000 Background: The role of secondary cytoreductive surgery in recurrent ovarian cancer (ROC)
has been under debate for decades. A recent trial in unselected patients (pts) failed to …
has been under debate for decades. A recent trial in unselected patients (pts) failed to …
Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.
…, S Greggi, PT Jensen, F Selle, F Guyon, C Pomel… - 2017 - ascopubs.org
5501 Background: The role of secondary cytoreductive surgery in recurrent ovarian cancer (OC)
has not been defined by level-1 evidence. Methods: Pts with OC and 1st relapse after 6…
has not been defined by level-1 evidence. Methods: Pts with OC and 1st relapse after 6…
Laparoscopic radical hysterectomy for invasive cervical cancer: 8-year experience of a pilot study
OBJECTIVES: The aim of this study was to retrospectively evaluate, in a series of 50
consecutive patients, the feasibility, morbidity, and survival outcome of the laparoscopic radical …
consecutive patients, the feasibility, morbidity, and survival outcome of the laparoscopic radical …
Cytoreductive surgery for advanced stages of ovarian cancer
J Dauplat, G Le Bouëdec, C Pomel… - Seminars in surgical …, 2000 - Wiley Online Library
During the past two decades, maximum cytoreductive surgery (also called debulking surgery)
has been the recommended surgical approach for advanced stages of ovarian carcinoma. …
has been the recommended surgical approach for advanced stages of ovarian carcinoma. …
Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric …
…, JM Classe, G Ferron, E Stoeckle, C Pomel… - International Journal of …, 2012 - ijgc.bmj.com
Objectives To evaluate the outcome of maximal cytoreductive surgery in patients with stage
IIIC to stage IV ovarian, tubal, and peritoneal cancer regarding overall survival (OS) and …
IIIC to stage IV ovarian, tubal, and peritoneal cancer regarding overall survival (OS) and …
[HTML][HTML] Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the …
…, E Lambaudie, A Floquet, V Fourchotte, C Pomel… - European journal of …, 2017 - Elsevier
Aim To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP)
helps achieve optimal debulking, measured by complete resection rate (CRR) at interval …
helps achieve optimal debulking, measured by complete resection rate (CRR) at interval …